Carbapenems are last-line antibiotics used to treat serious multidrug-resistant infections. Carbapenem-resistant P. aeruginosa (CRPA) infections are not susceptible to the effects of these antibiotics, and some are resistant to all available antibiotics. β-lactam antibiotics.

2023年5月23日 · These antibiotics are often used as the last line of treatment for infections caused by resistant Gram-negative bacteria including Pseudomonas aeruginosa. P. aeruginosa can carry genes encoding carbapenemases.

2024年10月8日 · What is carbapenem-resistant Pseudomonas aeruginosa (CRPA)? Pseudomonas infection is caused by strains of bacteria found widely in the environment. The most common type causing infections in humans is called Pseudomonas aeruginosa. Carbapenems are a class of antibiotics that were developed to …

2024年12月16日 · Carbapenemase genes were detected in 22% of the 972 strains from patients infected with carbapenem-resistant P aeruginosa, 3 with important variations according to geographical area, ranging from 2% in the USA, 2–37% in European countries, 4 and 30–60% in South and Central America, Australia, China, and the Middle East. 3.

2023年2月9日 · Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global threat, but the distribution and clinical significance of carbapenemases are unclear. The aim of this study was to define characteristics and outcomes of CRPA infections and the global frequency and clinical impact of carbapenemases harboured by CRPA.

2019年6月17日 · Carbapenem resistance in P. aeruginosa is due primarily to chromosomal mutations that alter porins, modify efflux pump activity, and derepress intrinsic β-lactamases. However, carbapenemase genes, commonly carried on mobile genetic elements, have the potential for rapid dissemination.

2023年1月3日 · It is responsible mainly for hospital-acquired infections (HAIs). It is Gram-negative, aerobic or facultative, glucose fermentative, motile, capsulated, and bacilli. Its ability to grow at 42 ° C and produce green pigmentation (due to pyocyanin pigment) helps identify and differentiate from other Pseudomonas spp.

Case patients infected with Carb-R/Ceph-S P. aeruginosa, carbapenem-susceptible and cephalosporin-susceptible (Carb-S/Ceph-S) P. aeruginosa, and controls with no P. aeruginosa bacteremia were compared at a ratio of 1:1:2. Real-time reverse transcription polymerase chain reaction was performed to assess resistance mechanisms.

Carbapenem-resistant Pseudomonas aeruginosa (CR-PA) is a major healthcare-associated pathogen worldwide. In the United States, 10-30% of P. aeruginosa isolates are carbapenem-resistant, while globally the percentage varies considerably.

2024年12月1日 · Carbapenem-resistant Pseudomonas aeruginosa (CRPA) and difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA) are used but which of them better correlate with the risk of mortality remains debated.